Polypeptide-engineered lipid nanoparticles for mRNA delivery with limited immunogenicity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42215480.
- Also identified by DOI 10.1038/s41467-026-73698-6.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lipid nanoparticles (LNPs) have shown great potential for mRNA delivery, with polyethylene glycol (PEG) lipids playing a critical role in modulating particle size, stability and biodistribution. However, most PEGylated LNPs induce anti-PEG antibodies, leading to hypersensitivity and diminished efficacy upon repeated administration. Here we report hydrophilic, nonionic and biodegradable poly(D, L-serine) (pDLS) lipids as PEG-lipid alternatives in LNP formulations. Through systematic structural screening, we identify optimal lipid architectures that yield colloidally stable pDLS-LNPs with high mRNA encapsulation and transfection efficiency. Compared to the clinically approved BNT162b2 formulation (ALC-LNP), pDLS-LNPs loaded with SARS-CoV-2 spike mRNA achieve superior mRNA delivery, and elicit robust cellular and humoral immune responses in mice, without inducing systemic toxicity. Notably, repeated dosing with pDLS-LNPs triggers minimal anti-pDLS IgM production, unlike PEG-based counterparts. Furthermore, pDLS-LNPs remain stable under frozen storage for over 6 months. These findings establish polypeptide-based pDLS-LNPs as promising, immunologically inert alternatives to PEGylated LNPs for safe and effective mRNA delivery.